Psoriasis is an inflammatory skin disease. Microneedle
(MN) patches
can improve psoriasis treatment outcomes by increasing local drug
content in the skin. As psoriasis frequently relapses, developing
intelligent MN-based drug delivery systems with prolonged therapeutic
drug levels and improved treatment efficiency is of great significance.
Here, we designed detachable H2O2-responsive
gel-based MN patches containing methotrexate (MTX) and epigallocatechin
gallate (EGCG) by using EGCG as both cross-linkers for needle-composited
materials and anti-inflammatory drugs. The gel-based MNs had dual-mode
drug release kinetics, which quickly released MTX diffusively and
sustainably released EGCG in an H2O2-responsive
way. Compared with dissolving MNs, the gel-based MNs extended skin
retention of EGCG, leading to prolonged reactive oxygen species (ROS)
scavenging effects. The ROS-responsive MN patches that transdermally
delivered antiproliferative and anti-inflammatory drugs improved treatment
outcomes in both psoriasis-like and prophylactic psoriasis-like animal
models.